A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients

References

• Farahmand M, Moghoofei M, Dorost A, et al. Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis. BMC Public Health. 2020;20:1455. doi:10.1186/s12889-020-09570-z32977797
   PubMed Web of Science ®Google Scholar
• Muñoz N, Castellsagué X, de González AB, Gissmann L, Castellsagué X. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl3):1–10. doi:10.1016/j.vaccine.2006.05.11516122853
   PubMed Web of Science ®Google Scholar
• Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445(1–2):224–231. doi:10.1016/j.virol.2013.07.01523928291
   PubMed Web of Science ®Google Scholar
• WHO. International Agency for Research on Cancer (IARC). IARC Monograph. Volume 100-B. Biological Agents. “Human Papillomaviruses – Epidemiology”. Published by the International Agency for Research on Cancer. Geneva 27, Switzerland: WHO Press, World Health Organization; 2012:255–313.
   Google Scholar
• Muñoz N, Méndez F, Posso H, et al. for the Instituto Nacional de Cancerologia HPV Study Group (2004). Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190:2077–2087. doi:10.1086/42590715551205
   PubMed Web of Science ®Google Scholar
• Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180:1415–1423. doi:10.1086/31508610515798
   PubMed Web of Science ®Google Scholar
• Dugué PA, Rebolj M, Garred P, Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther. 2013;13(1):29–42. doi:10.1586/era.12.15923259425
   PubMed Web of Science ®Google Scholar
• Conesa-Zamora P. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape. Gynecol Oncol. 2013;131(2):480–488. doi:10.1016/j.ygyno.2013.08.02523994536
   PubMed Web of Science ®Google Scholar
• Nguyen HH, Broker TR, Chow LT, et al. Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol. 2005;96(2):452–461. doi:10.1016/j.ygyno.2004.10.01915661235
   PubMed Web of Science ®Google Scholar
• Zhou C, Tuong ZK, Frazer IH. Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol. 2019;9:682. doi:10.3389/fonc.2019.0068231428574
   PubMed Web of Science ®Google Scholar
• Kovachev S. Immunotherapy in patients with local HPV infection and high-grade squamous intraepithelial lesion following uterine cervical conization. Immunopharmacol Immunotoxicol. 2020;42(4):314–318. doi:10.1080/08923973.2020.176537432429720
   PubMed Web of Science ®Google Scholar
• National Research Council. Treating Infectious Diseases in a Microbial World: Report of Two Workshops on Novel Antimicrobial Therapeutics. Washington, DC: The National Academies Press; 2006.
   Google Scholar
• Maus M, Fraietta J, Levine B, Kalos M, Zhao Y, June C. Adoptive immunotherapy for cancer or viruses. Ann Rev Immunol. 2014;32(1):189–225. doi:10.1146/annurev-immunol-032713-12013624423116
   PubMed Web of Science ®Google Scholar
• Monjazeb A, Hsiao HH, Sckisel G, Murphy W. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol. 2012;9(3):248–258. doi:10.3109/1547691X.2012.68552722734880
   PubMed Web of Science ®Google Scholar
• Bascones-Martinez A, Mattila R, Gomez-Font R, Meurman JH. Immunomodulatory drugs: oral and systemic adverse effects. Med Oral Patol Oral Cir Bucal. 2014;19(1):e24–e31. doi:10.4317/medoral.1908723986016
   PubMed Web of Science ®Google Scholar
• Ahmed RS, Newman AS, O’Daly J, et al. Inosine AcedobenDimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: a clinical trial supporting anti-viral indications. Int Immunopharmacol. 2017;42:108–114. doi:10.1016/j.intimp.2016.11.02327912146
   PubMed Web of Science ®Google Scholar
• Sudenga SL, Shrestha S. Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int J Infect Dis. 2013;17(4):e216–e220. doi:10.1016/j.ijid.2012.12.02723453716
   PubMed Web of Science ®Google Scholar
• Muñoz N, Hernandez-Suarez G, Méndez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer. 2009;100(7):1184–1190. doi:10.1038/sj.bjc.660497219293802
   PubMed Web of Science ®Google Scholar
• Bonde J, Bottari F, Iacobone AD, et al. Human papillomavirus same genotype persistence and risk: a systematic review. J Low Genit Tract Dis. 2021;25(1):27–37. doi:10.1097/LGT.000000000000057333105450
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type- specific human papillomavirus infections: the Young Women’s Health Study. J Infect Dis. 2002;186:462–469. doi:10.1086/34178212195372
   PubMed Web of Science ®Google Scholar
• Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87(18):1365–1371. doi:10.1093/jnci/87.18.13657658497
   PubMed Web of Science ®Google Scholar
• Venturoli S, Ambretti S, Cricca M, et al. Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol. 2008;80(8):1434–1440. doi:10.1002/jmv.2119818551620
   PubMed Web of Science ®Google Scholar
• Rachel Skinner S, Wheeler CM, Romanowski B, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138(10):2428–2438. doi:10.1002/ijc.2997126685704
   PubMed Web of Science ®Google Scholar
• Rositch AF, Koshiol J, Hudgens M, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer. 2013;133(6):1271–1285. doi:10.1002/ijc.2782822961444
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Castellsagué X, Garland SM, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One. 2013;8(11):e79260. doi:10.1371/journal.pone.007926024260180
   PubMed Web of Science ®Google Scholar
• Miranda PM, Silva NNT, Pitol BCV, et al. Persistence or clearance of human papillomavirus infections in women in OuroPreto, Brazil. Bio Med Res Int. 2013;2013:578276.
   Google Scholar
• Delvenne P. Rôle des réponsesimmunitairesdans les lésions (pré) néoplasiquescervicalesassociées aux papillomavirus humains [Immunologic response to (pre)neoplastic cervical lesions associated with human papillomavirus]. Bull Mem Acad R Med Belg. 2005;160(5–6):287–293. French.16465783
   PubMedGoogle Scholar
• Amador-Molina A, Hernández-Valencia JF, Lamoyi E, Contreras-Paredes A, Lizano M. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses. 2013;5(11):2624–2642. doi:10.3390/v511262424169630
   PubMed Web of Science ®Google Scholar
• Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr Probl Dermatol. 2014;45:58–74.24643178
   PubMedGoogle Scholar
• Smola S. Immunopathogenesis of HPV-associated cancers and prospects for immunotherapy. Viruses. 2017;9(9):254. doi:10.3390/v9090254
   PubMed Web of Science ®Google Scholar
• Barros MR, de Melo CML, Barros ML, de Cássia Pereira de Lima R, de Freitas AC, Venuti A. Activities of stromal and immune cells in HPV-related cancers. J Exp Clin Cancer Res. 2018;37(1):137. doi:10.1186/s13046-018-0802-729976244
   PubMed Web of Science ®Google Scholar
• Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res. 2007;33(2):103–113. doi:10.1111/j.1447-0756.2007.00492.x17441881
   PubMed Web of Science ®Google Scholar
• Woodby B, Scott M, Bodily J. The interaction between human papillomaviruses and the stromal microenvironment. Prog Mol Biol Transl Sci. 2016;144:169–238.27865458
   PubMed Web of Science ®Google Scholar
• Deligeoroglou E, Giannouli A, Athanasopoulos N, et al. HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol. 2013;2013:540850. doi:10.1155/2013/54085024023507
   PubMedGoogle Scholar
• Lee SJ, Yang A, Wu TC, Hung CF. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol. 2016;27(5):e51. doi:10.3802/jgo.2016.27.e5127329199
   PubMed Web of Science ®Google Scholar
• Barros MR, de Oliveira THA, de Melo CML, Venuti A, de Freitas AC. Viral modulation of TLRs and cytokines and the related immunotherapies for HPV-associated cancers. J Immunol Res. 2018;2018:2912671. doi:10.1155/2018/291267129854832
   PubMed Web of Science ®Google Scholar
• Singh M, Thakral D, Rishi N, Kar HK, Mitra DK. Functional characterization of CD4 and CD8 T cell responses among human papillomavirus infected patients with anogenital warts. Virus Dis. 2017;28(2):133–140. doi:10.1007/s13337-017-0382-8
   Google Scholar
• Nasu K, Narahara H. Pattern recognition via the toll-like receptor system in the human female genital tract. Mediat Inflamm. 2010;2010:976024. doi:10.1155/2010/976024
   PubMed Web of Science ®Google Scholar
• Yang K, Puel A, Zhang S, et al. Human TLR-7-, −8-, and −9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity. 2005;23:465–478. doi:10.1016/j.immuni.2005.09.01616286015
   PubMed Web of Science ®Google Scholar
• Miller LS, Modlin RL. Human keratinocyte Toll-like receptors promote distinct immune responses. J Investig Dermatol. 2007;127:262–263. doi:10.1038/sj.jid.570055917228303
   PubMed Web of Science ®Google Scholar
• Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother. 2012;18(6):807–815. doi:10.1007/s10156-012-0485-523117294
   PubMed Web of Science ®Google Scholar
• Sparber F. Langerhans cells: an update. J Germ Soc Dermatol. 2014;12(12):1107–1111.
   Google Scholar
• Woo YL, van den Hende M, Sterling JC, et al. A prospective study on the natural course of lowgrade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer. 2010;126(1):133–141. doi:10.1002/ijc.2480419645010
   PubMed Web of Science ®Google Scholar
• Vici P, Pizzuti L, Mariani L, et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines. 2016;15(10):1327–1336. doi:10.1080/14760584.2016.117653327063030
   PubMed Web of Science ®Google Scholar
• You Y, Wang L, Li Y, et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015;42(6):596–601. doi:10.1111/1346-8138.1284525819042
   PubMed Web of Science ®Google Scholar
• Brzeski M, Madhok R, Hunter JA, Capel HA. Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis. Ann Rheum Dis. 1990;49:293–295. doi:10.1136/ard.49.5.2931693065
   PubMed Web of Science ®Google Scholar
• Sliva J, Pantzartzi CN, Votava M. Inosine pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases. Adv Ther. 2019;36(8):1878–1905. doi:10.1007/s12325-019-00995-631168764
   PubMed Web of Science ®Google Scholar
• Petrova M, Jelev D, Ivanova A, Krastev Z. Isoprinosine affects serum cytokine levels in healthy adults. J Interferon Cytokine Res. 2010;30(4):223–228. doi:10.1089/jir.2009.005720038210
   PubMed Web of Science ®Google Scholar
• Lasek W, Janyst M, Wolny R, Zapala L, Bocian K, Drela N. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm. 2015;65(2):171–180. doi:10.1515/acph-2015-001526011933
   PubMed Web of Science ®Google Scholar
• Milano S, Dieli M, Millott S, Miceli MD, Maltese E, Cillari E. Effect of isoprinosine on IL-2, IFN-gamma and IL-4 production in vivo and in vitro. Int J Immunopharmacol. 1991;13(7):1013–1018. doi:10.1016/0192-0561(91)90055-C1722191
   PubMed Web of Science ®Google Scholar
• Tsang KY, Pan JF, Swanger DL, Fudenberg HH. In vitro restoration of immune responses in aging humans by isoprinosine. Int J Immunopharmacol. 1985;7(2):199–206. doi:10.1016/0192-0561(85)90027-X2409037
   PubMed Web of Science ®Google Scholar
• Sabat R, Grutz G, Warszawska K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21(5):331–344. doi:10.1016/j.cytogfr.2010.09.00221115385
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Kosuzume H, Inaba H, Ohkura M, Shimada S, Suzuki Y. The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections. Int J Immunopharmacol. 1983;5(3):181–196. doi:10.1016/0192-0561(83)90055-36194125
   PubMed Web of Science ®Google Scholar
• Isoprinosine. Summary of product characteristics. Ewopharma International; 2003. Available from: http://www.doctoronline.bg. Accessed 528, 2021.
   Google Scholar
• Renoux G, Renoux M, Guillaumin J-M. Isoprinosine as an immunopotentiator. J Immunopharmacol. 1979;1(3):337–356. doi:10.3109/0892397790902637995412
   PubMedGoogle Scholar
• Krastev Z, Jelev D, Ivanova R. Isoprinosine induces a rapid lympho-mononuclear response in adult participants. Med Inf. 2015;2(1):80–85.
   Google Scholar
• Corey L, Chiang W, Reeves W, Stamm W, Brewer L, Holmes K. Effect of isoprinosine on the cellular immune response in initial genital herpes virus infection. Clin Res. 1979;27:41A.
   Google Scholar
• Galbraith GM, Thiers BH, Fudenberg HH. An openlabel trial of immunomodulation therapy with inosiplex (Isoprinosine) in patients with alopecia totalis and cell-mediated immunodeficiency. J Am Acad Dermatol. 1984;11(2):224–230. doi:10.1016/S0190-9622(84)70153-86207216
   PubMed Web of Science ®Google Scholar
• Cianciara J, Laskus T, Gabinska E, Loch T. Isoprinosine in the treatment of chronic active hepatitis type B. Scand J Infect Dis. 1990;22(6):645–648. doi:10.3109/003655490090271151704640
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Turgonyi E, Kumar A, Lim W, Larocque L, Hyde BM. Clinical improvement in chronic fatigue syndrome is associated with enhanced natural killer cell-mediated cytotoxicity: the results of a pilot study with isoprinosine. J Chronic Fatigue Syndr. 2003;11(2):71–95. doi:10.1300/J092v11n02_06
   Google Scholar
• Sadoul G, Beuret TH. Treatment of cervical and vulvar condylomata by СО2 laser also with a immunostimulant. Rev Fran Gynecol Obstet. 1984;79(11):681–684.
   PubMedGoogle Scholar
• Mohanty KC, Scott CS. Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study. Sex Transmit Infect. 1986;62:352–355. doi:10.1136/sti.62.5.352
   Google Scholar
• Davidson-Parker J, Dinsmore W, Khan MH, Hicks DA, Morris CA, Morris DF. Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study. Genitourin Med. 1988;64(6):383–386. doi:10.1136/sti.64.6.3832465265
   PubMedGoogle Scholar
• Nejmark BA, Kondrateva JS, Zologina VS, Torbik DV. Effectiveness of combined treatment of HPV infection. Urologia. 2015;(2):39–40,42.
   Google Scholar
• Tay SK. Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study. Int J STD AIDS. 1996;7(4):276–280. doi:10.1258/09564629619179608876359
   PubMed Web of Science ®Google Scholar
• Rakhmatulina MR. Combination therapy for papillomavirus infection. Akusherstvoi Ginekologiya/Obstet Gynecol. 2017;12:122–125. Russian.
   Google Scholar
• Budanov PV, Churganova AA, Bakhtiyarov KR, Strizhakov AN. Human papillomavirus infection: the efficacy of treatment with inosine pranobex. Gynecology. 2015;17(6):56–59. doi:10.26442/2079-5696_17.6.56-59
   Google Scholar
• Bitsadze VO, Khamani NM, Makatsariya NA. Role of inosine pranobex in management of HPV-associated diseases: problems and prospective. Obstet Gynecol Reprod. 2016;10(3):76–84. Russian. doi:10.17749/2313-7347.2016.10.2.076-084
   Google Scholar
• Prilepskaya VN, Rogovskaya SI. Possibilities of isoprinosine in treatment of chronic cervicitis and vaginitis. Russ Med J. 2008;16(1):5–9.
   Google Scholar
• Linask LI, Grigorieva EE. Experience of the use of Isoprinosin against cervical diseases in the adolescents and young women with papillomavirus infection. Russ Med J. 2008;16(19):1221–1225.
   Google Scholar
• Eliseeva MY, Manukhin IB, Mynbaev OA, Zvereva NS, Mishutina AA, Tcarev VN. Antiviral effect of isoprinosine in HPV-associated diseases. Obstet Gynecol. 2012;2:107–114.
   Google Scholar
• Pestrikova TY, Pushkar VA. Evaluation of comprehensive treatment of cervical pathology associated with HPV. Gynecol. 2015;17(1):50–53. doi:10.26442/2079-5831_17.4.50-53
   Google Scholar
• Pestrikova TY, Panfilova YO, Yurasova EA, Kotelnikova AV. Assessment of viral load in patients with HPV-associated cervicitis during the course of complex treatment. Gynecology. 2017;19(3):45–48.
   Google Scholar
• Ordiyants IM, Buyanova NV, Abdurakhmanova MB. Recurrence of HPV infection after combination therapy of uterine cervical diseases. Obstet Gynecol News Opin Train. 2018;6(3):47–52.
   Google Scholar
• Kedrova AG, Podisov YI, Kuznetsov VV, Bryugzin VV, Kozachenko VP, Nikogosyan SO. Role of antiviral therapy in the complex treatment of patients with epithelial dysplasias and preinvasive cancer of the cervix uteri. Akush Ginekol. 2006;6:27–30.
   Google Scholar
• Kedrova AG. Local immunosuppressive damage in the human papillomavirus persistence. RMJ. 2017;26:1971–1976.
   Google Scholar